FDA grants fast-track status to GI ARS drug by Soligenix

01/31/2013 | Pharmaceutical Business Review Online

Soligenix's OrbeShield obtained fast-track designation from the FDA as treatment for gastrointestinal acute radiation syndrome. The drug has already won orphan-drug status to prevent death after a lethal or high dose of irradiation from a disaster.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD